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Background: Preeclampsia is associated with an increased risk of hypertension later in life. The regulator of G
protein signaling 2 negatively regulates several vasoconstrictors. We recently demonstrated an association between
preeclampsia and the CG or GG genotype of the C1114G polymorphism (rs4606) of the regulator of G protein
signaling 2 gene. Here, we examined the polymorphism with respect to the development of hypertension after
pregnancy.
Methods: We genotyped 934 women on average 15.1 years after preeclampsia and 2011 age matched women with
previous normotensive pregnancy. All women in this study were retrospectively recruited from the Nord-Trøndelag
Health Study (HUNT2). Information from HUNT2 was linked to the Medical Birth Registry of Norway to identify women
with a history of preeclampsia and women without a history of preeclampsia.
Results: No significant association was found between hypertension (blood pressure ≥140/90 mmHg and/or taking
antihypertensive drugs) and the polymorphism in crude analysis (OR (95% CI): CG genotype: 1.07 (0.90-1.27); GG
genotype: 1.23 (0.90-1.67)). However, in a minimally adjusted model (age and BMI adjusted), a significant association
between the GG genotype and hypertension was found (OR (95% CI): 1.49 (1.05-2.11)). This association remained
significant also after adjustment for a history of preeclampsia (OR (95% CI): 1.46 (1.02-2.09)), but not in a model
adjusted for multiple other variables (OR (95% CI): 1.26 (0.82-1.94)). In multivariate, but not in crude, analysis, the GG
genotype of rs4606 (OR (95% CI): 1.93 (1.05-3.53)) was significantly and independently associated with severe
hypertension later in life, defined as systolic blood pressure ≥160 mmHg (stage 2 hypertension) and/or taking
antihypertensive drugs. A significant association was also found for the merged CG and GG genotypes (OR (95% CI):
1.43 (1.02-2.00)). Moreover, an interaction with physical activity was found. A history of preeclampsia was a significant
and independent predictor of either definition of hypertension, both in crude and adjusted analyses.
Conclusion: Women carrying the rs4606 CG or GG genotype are at elevated risk for developing hypertension after
delivery. Physical activity may interact with the association. Preeclampsia remains an independent risk factor for
subsequent hypertension after adjusting for this polymorphism and classical CVD risk factors.
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Preeclampsia affects approximately 2-8% of all pregnan-
cies [1] and is clinically manifested as proteinuria and
hypertension after 20 weeks of gestation [2]. Preeclamp-
sia is recognized as a risk factor for hypertension and
cardiovascular disease (CVD) later in life [3], with early-
onset (with delivery prior to gestational week 34) and
recurrent episodes of preeclampsia being even more
strongly associated with later CVD [4]. The mechanistic
links between preeclampsia and future health are incom-
pletely elucidated. Common predisposition, genetic or
environmental, that could contribute to the development
of both preeclampsia and hypertension or CVD later in
life, is a possible explanatory link. In line with this, clas-
sical CVD risk factors such as obesity, dyslipidemia, insu-
lin resistance, family history and endothelial dysfunction
are also associated with preeclampsia [3]. A pregnancy
complicated by preeclampsia as a direct causal factor, or
an “amplifying factor” for the association, can also not be
ruled out.
The regulator of G protein signaling 2 (RGS2) acts as
a GTP-ase activating protein for Gαq proteins and is
thereby involved in controlling the termination of vaso-
constrictor signaling initiated by ligands such as Angio-
tensin II (Ang II) [5]. Hercule et al. showed that RGS2
deletion promotes Ang II-dependent hypertension pri-
marily through an increase of myogenic tone and va-
soreactivity, probably by sensitization of Ang II type 1
receptor (AT1-receptor) [6]. The G allele of a poly-
morphism (rs4606) in the three prime untranslated re-
gion of RGS2 has previously been associated with
reduced RGS2 expression [7]. This study, which included
both men and women, also found that those with hyper-
tension more often carried the G allele compared to
normotensive controls [7]. We recently identified the
CG or GG genotype to be more common among women
with preeclampsia compared to women without pre-
eclampsia [8]. This difference in the genotype distribu-
tion between cases and controls could possibly also
contribute to the increased risk of hypertension later in
life in women with a history of preeclampsia. Based on
the majority of our previous study population, the
population-based HUNT2 study, we wanted to explore
whether rs4606 in RGS2 is associated with development
of hypertension after pregnancy, which to our know-
ledge has not been investigated previously.
Methods
Study population
All women in this study (n = 2945) were retrospectively
recruited from the phase 2 of the Nord-Trøndelag Health
Study (the HUNT2 Survey). HUNT2 is a large multipur-
pose health survey conducted in 1995–1997, where all
residents ≥ 20 years old living in Nord-Trøndelag county,Norway, were invited, and a total of 75.5% (n = 35,280) of
the invited women participated [9]. Clinical information
was collected from self-reported questionnaires, which
included questions on the use of antihypertensive medica-
tion, physical activity, smoking and diseases such as CVD
and diabetes mellitus. A standardized clinical examination
included height, weight and blood pressure measure-
ments. Blood pressure was measured using an automatic
oscillometric method (Dina map 845XT; Critikon) after
participants had rested in the sitting position for a mini-
mum of two minutes. Three subsequent readings were
taken at intervals of one minute [9] and the average of the
second and third readings were used in the present study.
Serum lipids (including total cholesterol and high density
lipoprotein (HDL)) were measured in non-fasting venous
blood samples and DNA was isolated from peripheral
blood [9].
We linked information from HUNT2 with the Medical
Birth Registry of Norway (MBRN). MBRN registers all
deliveries in Norway since 1967 by compulsory notifica-
tion, and the diagnosis of preeclampsia in the MBRN is
based on the individual delivery reports from the deliv-
ering units. Delivery units in Norway presently use the
American College of Obstetricians and Gynecologist
(ACOG) criteria for a diagnosis of preeclampsia; systolic
blood pressure ≥140 mmHg or diastolic blood pres-
sure ≥90 mmHg that occurs after 20 weeks of gestation
in a previously normotensive woman, combined with
proteinuria (urinary excretion of ≥ 0.3 g protein in a
24-hour urine specimen) [2]. As cases, we selected indi-
viduals with a diagnosis of preeclampsia in MBRN prior
to participation in HUNT2, who also had an available
DNA sample at HUNT Biobank. A validation study of
the diagnosis of preeclampsia against the medical re-
cords for participants in the HUNT2 study that were
previously selected for two different genetic studies of
preeclampsia has recently been published [10]. In this
study, a diagnosis of preeclampsia was confirmed in
88.3% of pregnancies during 1967–2002, and in 63.6%
of pregnancies during 1967–2005, using the broader
and traditional criteria of one measurement of hyper-
tension and proteinuria versus today’s criteria of two re-
peated measurements of proteinuria and hypertension
respectively [10], suggesting an acceptable validation
of the preeclampsia diagnosis in the HUNT2 study.
Absence of a medical chart documented proteinuria
accounted for more than 70% of a non-confirmed pre-
eclampsia diagnose [10], not necessarily excluding a history
of proteinuria and thereby a diagnosis of preeclampsia.
As controls (≈2:1 controls per case), we selected women
with at least one delivery prior to participating in the
HUNT2 study, who also had available DNA at HUNT
Biobank and never were registered with preeclampsia in
the MBRN. Hence, we only included women with at least
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for the preeclampsia cases), in order to address the asso-
ciations of preeclampsia, as well as genotype associations
with hypertension. In order to avoid any potential im-
mediate effects of the preeclamptic pregnancy on the
association to postpartum hypertension, we selected
individuals registered in MBRN that delivered with a
diagnosis of preeclampsia at least one year prior to par-
ticipation in HUNT2. Mean duration since the pre-
eclamptic index pregnancy was 15.1 years (SD: 8.51,
range: 1.0-31.0 years) at the time of inclusion in the
HUNT2 study. Controls were matched for age to the
index preeclampsia pregnancy.
We excluded individuals with missing information re-
garding whether or not they were taking any antihyper-
tensive drugs at the time of enrollment in the HUNT2
study (not excluded in our previous paper studying risk
of preeclampsia) [8] as well as missing information from
MBRN of pregnancy duration at delivery. We also ex-
cluded women that at the time of index delivery in the
MBRN had chronic hypertension, chronic renal disease,
heart disease, or diabetes mellitus prior to pregnancy, and
women with registered non-proteinuric gestational hyper-
tension. The final study population consisted of 2945
women; 934 with a history of preeclampsia and 2011
women with a history of normotensive pregnancies.
The HUNT2 study was conducted according to the
principles expressed in the Declaration of Helsinki. At-
tendance was voluntary, and each participant signed a
written informed consent including information on gen-
etic analyses. The study was approved by the Regional
Committees for Medical and Health Research Ethics
(REC Central), Norway.
SNP analyses
DNA was extracted and rs4606 was analyzed with the
TaqMan®-based single nucleotide polymorphism genoty-
ping technology (assay ID: C__2498717_10) using 7900HT
Fast RealTime PCR System (Applied Biosystems, Foster
City, CA), as previously described [8].
Statistical analyses
Data were analyzed using Predictive Analytics Soft Ware
(version 18.0.1, SPSS Inc, Chicago, IL, USA). We applied
the independent samples t-test to test for differences in
continuous variables between groups and data are pre-
sented as mean and standard deviation (SD). Associa-
tions between categorical variables were tested by use of
chi-square statistics (X2 test) or binary logistic regres-
sion. Proportions are given in percentages and risk esti-
mates are given as odds ratios (OR) with 95% confidence
intervals (CI).
We defined current hypertension (at HUNT2 Study)
as systolic blood pressure ≥140 mmHg and/or diastolicblood pressure ≥ 90 mmHg and/or taking antihyperten-
sive drugs, and used it as the outcome variable in logistic
regression analysis. Additionally, we tested the outcome
variables according to stage 2 hypertension, defined by
the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC7) [11]; SBP ≥ 160 mmHg and DBP ≥
100 mmHg; separately, in combination and/or combined
with those taking antihypertensive drugs. Classical CVD
risk factors, as well as parity, a history of preeclampsia and
the rs4606 SNP, were included as explanatory variables in
the multivariate models.
Due to low numbers for some of the variables and
categories, some of the categorical variables were re-
categorized into fewer categories than the original co-
ding. The three genotypes (CC, CG and GG) of rs4606,
as well as merged into two categories (CC and CG +GG),
were tested in separate models. In either case, the CC
genotype was used as reference. Continuous variables in
the main effects models were analyzed for linearity and
categorized if indicated. Potential interaction terms were
tested as the product between rs4606 genotypes and each
of the other remaining explanatory variables in the main
effects model. The final models were found sound when
tested for Hosmer-Lemeshow goodness of fit (P > 0.05).
Results
Genotype distribution
As previously shown, the genotype distribution was signifi-
cantly different between the preeclampsia group (with CC:
47.5% (n = 444); CG: 44.6% (n = 417); GG: 7.8% (n = 73))
compared to the control group (with CC: 53.5% (n = 1075);
CG: 39.0% (n = 785); GG: 7.5% (n = 151)), P = 0.009 (the
numbers differing slightly from our previous paper due to
modified inclusion criteria, see Methods) [8].
Clinical characteristics in women with a history of
preeclampsia versus normotensive pregnancy
At inclusion in the HUNT2 study, known CVD risk fac-
tors were higher (BMI, lipids, blood pressure) or more
prevalent (diabetes mellitus) in women with a history of
preeclampsia compared to the control group (Table 1).
Prevalence of current hypertension, including current
use of antihypertensive drugs, was also higher in the
group of women with previous preeclampsia compared
to the control group (Table 1). The proportion of cur-
rent smokers was higher in the control group com-
pared to the previous preeclampsia group (Table 1).
Age at inclusion in the HUNT2 study did not differ be-
tween the preeclampsia and the control group (Table 1).
Women with a history of preeclampsia and current hyper-
tension were younger than women with current hyper-
tension and previous normotensive pregnancy (46.3 (SD:
9.65) years, versus 49.4 (SD: 10.0) years, P < 0.001).
Table 1 Clinical data at HUNT2 inclusion for women with a history of preeclampsia vs. control group
Preeclampsia Control P
Age, mean (SD) 41.0 (9.81) 41.2 (10.8) 0.588
Parities, % (n)
1 13.2 (123) 16.7 (336)
≥ 2 86.8 (811) 83.3 (1675) 0.014
Pregnancy duration at delivery in weeks, mean (SD) 38.8 (2.76) 39.8 (2.29) <0.001*
Delivery < 37 weeks gestation, % (n) 14.6 (136) 4.5 (91) <0.001*
Delivery < 34 weeks gestation, % (n) 5.4 (50) 1.7 (34) <0.001*
SBP, mean (SD)† 133.5 (19.7) 126.3 (17.6) <0.001*
DBP, mean (SD)† 80.6 (11.9) 75.7 (11.0) <0.001*
Hypertension, % (n)‡ 37.7 (352) 21.7 (436) <0.001*
SBP ≥ 140 mmHg, % (n)§ 27.1 (228) 16.4 (316) <0.001*
DBP≥ 90 mmHg, % (n)§ 18.1 (152) 8.2 (158) <0.001*
SBP ≥ 160 mmHg, % (n)§ 8.0 (67) 4.2 (81) <0.001*
DBP ≥ 100 mmHg, % (n)§ 5.0 (42) 2.2 (42) <0.001*
Antihypertensive drugs: % (n) Current: 9.9 (92) Current: 4.3 (86)
Previous: 13.3 (124) Previous: 1.60 (32)
Never: 77 (718) Never: 94.1 (1893) <0.001*
BMI, mean (SD) 27.9 (5.42) 25.8 (4.37) <0.001*
Serum Cholesterol, mean (SD) 5.63 (1.12) 5.59 (1.24) 0.387
HDL, mean (SD) 1.45 (0.37) 1.49 (0.37) 0.022*
Total Cholesterol/HDL, mean (SD) 4.12 (1.36) 3.99 (1.40) 0.020*
Current smoker, % (n) 26.5 (234) 38.4% (741) <0.001*
Diabetes, % (n) 3.1 (29) 1.0 (20) <0.001*
CVD, % (n) 1.1 (10) 1.2 (25) 0.695
*Statistically significant P < 0.05. †Regardless of taking antihypertensive drugs or not. ‡SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or current use of
antihypertensive drugs. §Included in analysis only those women not pharmacologically treated for hypertension.
SBP: Systolic blood pressure. DBP: diastolic blood pressure. BMI: Body mass index. HDL: High density lipoprotein. CVD: Cardiovascular disease (= a current or past
diagnosis of angina pectoris, myocardial infarction or cerebral stroke).
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rs4606 genotype groups, neither in the total study popula-
tion (preeclampsia + controls), nor within the preeclamp-
sia and control group separately (all non-significant; data
not shown).
Risk of hypertension according to obstetric history and
genotype
Table 2 shows the association between the rs4606 poly-
morphism and hypertension after pregnancy (in women
that were without registered chronic disease prior to
pregnancy). Results are given for the total study population,
as well as for subgroups according to obstetric history. In
addition to unadjusted results, minimally adjusted results
with adjustment for age and age + BMI are given, as age
and BMI are considered major predictors for hypertension.
In unadjusted analysis, no significant association was found
between any of the genotypes and hypertension at HUNT2
inclusion in the total study population (Table 2). However,a significant association was found between the GG
genotype and hypertension after adjustment for age, and
age + BMI (Table 2). A marginally significant association
was also found between the GG genotype and hypertension
in the group of women with a history of preeclampsia,
whereas the association was weaker in the control group
(Table 2). Based on the total study population, the associa-
tion between the GG genotype and hypertension remained
however significant if a history of preeclampsia was ac-
counted for (OR (95% CI): 1.46 (1.02-2.09), P = 0.037), but
was attenuated in a model adjusted for multiple other
variables (main effects model with the following additional
variables: total cholesterol/HDL cholesterol ratio, CVD,
diabetes and hard physical activity; CG: OR (95% CI): 1.15
(0.91-1.46), P = 0.230; GG: OR (95% CI): 1.26 (0.82-1.94),
P = 0.297). A history of preeclampsia remained an inde-
pendent predictor for current hypertension also in the
multivariate model, including adjustment for the rs4606
variable (OR (95% CI): 2.22 (1.76-2.80), P < 0.001).
Table 2 rs4606 and risk of hypertension (SBP ≥ 140 mmHg/DBP ≥ 90 mmHg and/or taking antihypertensive drugs)
according to obstetric history
Unadjusted Age-adjusted Age and BMI-adjusted
Obstetric
history group
OR (95% CI)† P Number
included in
analysis (n)
OR (95% CI)† P Number
included in
analysis (n)
OR (95% CI)† P Number
included in
analysis (n)
Preeclampsia +
control
CG: 1.07
(0.90-1.27)
0.451 2945 CG: 1.10
(0.91-1.33)
0.321 2945 CG: 1.12
(0.92-1.36)
0.254 2937
GG: 1.23
(0.90-1.67)
0.193 GG: 1.41
(1.01-1.97)
0.047* GG: 1.49
(1.05-2.11)
0.027*
Control CG: 0.998
(0.80-1.25)
0.989 2012 CG: 1.07
(0.84-1.36)
0.604 2012 CG: 1.07
(0.83-1.38)
0.595 2007
GG: 1.02
(0.68-1.54)
0.923 GG: 1.23
(0.78-1.92)
0.369 GG: 1.28
(0.80-2.04)
0.303
Preeclampsia CG: 1.07
(0.81-1.41)
0.653 933 CG: 0.98
(0.72-1.33)
0.897 933 CG: 1.03
(0.76-1.41)
0.838 930
GG: 1.53
(0.93-2.52)
0.094 GG: 1.61
(0.93-2.80)
0.091 GG: 1.76
(1.00-3.11)
0.052
Early-onset
preeclampsia
CG: 3.30
(0.87-12.5)
0.079 50 CG: 4.50
(0.93-21.9)
0.062 50 CG: 7.90
(1.30-48.2)
0.025* 50
CG/GG: 3.38
(0.90-12.6)‡
0.070 CG/GG: 4.68
(0.98-22.3)‡
0.053 CG/GG: 7.96
(1.33-47.8)‡
0.023*
Later onset
preeclampsia
CG: 1.01
(0.76-1.34)
0.946 883 CG: 0.913
(0.67-1.25)
0.570 883 CG: 0.95
(0.69-1.31)
0.761 880
GG: 1.47
(0.88-2.43)
0.139 GG: 1.53
(0.87-2.68)
0.137 GG: 1.68
(0.94-2.98)
0.079
Recurrent
preeclampsia
CG: 1.98
(0.98-4.01)
0.058 158 CG: 1.73
(0.84-3.58)
0.139 158 CG: 1.66
(0.79-3.49)
0.183 158
CG/GG: 2.04
(1.03-4.03)ǂ
0.040* CG/GG: 1.78
(0.89-3.59)ǂ
0.106 CG/GG: 1.81
(0.88-3.71)ǂ
0.105
Non-recurrent
preeclampsia
CG: 0.95
(0.70-1.29)
0.747 775 CG: 0.871
(0.62-1.23)
0.428 775 CG: 0.94
(0.66-1.33)
0.710 772
GG: 1.43
(0.82-2.49)
0.212 GG: 1.58
(0.84-2.98)
0.159 GG: 1.62
(0.85-3.12)
0.145
*Statistically significant P < 0.05. SBP: Systolic blood pressure. DBP: Diastolic blood pressure. †Reference genotype: CC. ‡Merging of CG + GG genotype (n = 28)
due to low numbers in GG genotype group (n = 2).
ǂMerging of CG + GG genotype (n = 91) due to low numbers in GG genotype group (n = 15). Non-recurrent preeclampsia: primiparas and multiparas with only
one preeclamptic pregnancy.
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cant association was found between the CG or GG
genotype and hypertension in the early-onset (delivery
prior to gestational week 34) preeclampsia group after
adjustment for age and BMI (Table 2). In unadjusted
analysis, a significant association was found between the
CG or GG genotype and hypertension in the recurrent
preeclampsia group (Table 2). No significant association
was found between the genotypes and hypertension in
the later onset (delivery from gestational week 34 and
onwards) preeclampsia group or the non-recurrent pre-
eclampsia group (Table 2). As some of the preeclampsia
subgroups were very small (such as the early-onset and re-
current preeclampsia groups), limiting statistical power,
further multivariate adjustment for an association between
rs4606 and hypertension was not carried out for each of
these sub-groups separately.Association between stage 2 hypertension, the rs4606
polymorphism and preeclampsia
In multivariate (but not in crude) analysis, we found a
significant association between the rs4606 GG genotype
and current stage 2 (severe) hypertension, defined as
SBP ≥ 160 mmHg and/or current use of antihypertensive
drugs. One-hundred-and-fifty-nine (16.8%) women with a
history of preeclampsia were classified according to this
definition of hypertension, compared to 170 (8.3%) women
with a history of normotensive pregnancy (P < 0.001).
Table 3 shows the association in the unadjusted model, a
minimally adjusted model, a fully adjusted model (“multi-
variate model”) as well as a model containing only variables
significant at 5% level (“main effects model”; variables ex-
cluded from the larger model were not found to be con-
founders for the association between the rs4606 variable
and hypertension). A significant association for the same
Table 3 Logistic regression model (outcome variable: systolic blood pressure ≥160 mmHg and/or taking
antihypertensive drugs)
n OR 95% CI P
Lower Upper
rs4606 genotype‡ (unadjusted) 2944
CG 1.03 0.81 1.31 0.834
GG 1.02 0.66 1.60 0.921
Minimally adjusted model# 2936
rs4606 genotype‡
CG 1.00 0.76 1.32 0.978
GG 1.16 0.69 1.93 0.582
Multivariate model† 2123
rs4606 genotype‡
CG 1.38 0.96 1.99 0.083
GG 1.88 1.02 3.47 0.044*
Main effects model§ 2211
rs4606 genotype‡
CG 1.36 0.96 1.92 0.088
GG 1.93 1.05 3.53 0.033*
History of preeclampsia vs. control 3.27 2.32 4.60 <0.001*
Age 1.13 1.11 1.15 <0.001*
Hard Physical activity 0.58 0.39 0.88 0.010*
BMI ≥ 25 2.38 1.60 3.53 0.001*
Diabetes 5.14 2.31 11.4 <0.001*
*Statistically significant P < 0.05. ‡Reference: CC genotype. #Age and BMI from HUNT2 and a history of preeclampsia were included in the minimally adjusted
model in addition to the rs4606. †In addition to the rs4606, a history of preeclampsia and the following variables from HUNT2 were included in the multivariate
model: age, CVD ever (= a current or past diagnosis of angina pectoris, myocardial infarction or cerebral stroke; Yes/No), Diabetes ever (Yes/No), Smoking
cigarettes (Yes/No), Number of children (≥ 2 vs. 1), Hard physical activity (≥ 1 h/week vs. <1 h/week), BMI, Total Cholesterol/HDL-ratio. §Main effects model
includes only variables significant at P < 0.05. BMI = Body mass index.
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GG genotypes of rs4606 were merged into one group
(“main effects model”: OR (95% CI): 1.43 (1.02-2.00), P =
0.036). The association between rs4606 and stage 2 hyper-
tension remained also significant if we added DBP ≥
100 mmHg to the definition, but the polymorphism was
not significantly associated with diastolic hypertension
alone (data not shown). The association between the poly-
morphism and stage 2 systolic hypertension (as defined in
Table 3) was also of same magnitude if analyses were car-
ried out separately for women with a history of preeclamp-
sia: OR (95% CI): CG: 1.36 (0.83-2.24), P = 0.224 and GG:
2.09 (0.90-4.87), P = 0.088 and controls: OR (95% CI):
CG: 1.30 (0.79-2.13), P = 0.304 and GG: 1.82 (0.75-4.39),
P = 0.184. Moreover, a history of preeclampsia remained a
significant and independent predictor for current hyperten-
sion after multivariate adjustments, for all alternative cri-
teria used in this study to define hypertension.
Interaction between rs4606 and physical activity
Of the tested interactions, a significant interaction term
was found between the combined CG and GG genotypegroup and hard physical activity with respect to current
stage 2 hypertension (as defined in Table 3), with an OR
of 3.09 (95% CI: 1.35-7.09), P = 0.008. The interaction
term remained significant also if we adjusted for age at
HUNT2 inclusion and obstetric history (preeclampsia
versus normotensive pregnancy; data not shown). To in-
vestigate this further, we next stratified our analyses into
those exercising 0- <1 h/week (named inactive women)
and those exercising ≥1 h/week (named active women).
We found that, in physically inactive women, the preva-
lence of hypertension did not differ significantly between
those having the CC compared to those having the CG/
GG genotype. In physically active women however, the
prevalence of hypertension was significantly lower in CC
versus CG/GG genotype carriers (Table 4). We found a
similar trend if we did the same stratification, but
defined hypertension as systolic blood pressure ≥140
mmHg and/or diastolic blood pressure ≥90 mmHg and/
or current use of antihypertensive drugs (Table 5). In
either case, the prevalence of hypertension was lower
in physically active women as compared to physically
inactive women, but this difference was statistically
Table 4 Prevalence of women with stage 2 hypertension according to rs4606 genotypes and physical activity/inactivity
stratification
Systolic blood pressure ≥160 mmHg and/or taking antihypertensive drugs (% (n))
Hard physical activity CC CG/GG P†
0 - < 1 h/week 10.0 (81) 11.2 (83)§ 0.442
≥ 1 h/week 2.7 (9) 8.8 (29)# 0.001*
P‡ <0.001* 0.228
*Statistically significant P < 0.05 (Pearson chi-square). †CG/GG genotypes vs. CC genotype. ‡Physically active (≥ 1 h/week) vs. physically inactive (0 - < 1 h/week).
§Thereof GG genotype: n = 16. #Thereof GG genotype: n = 3.
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Table 5).
Discussion
In 2011, The American Heart Association added preg-
nancy complications such as preeclampsia to the list of
risk factors for developing CVD [12]. A mechanistic ex-
planation for the relationship between preeclampsia and
later CVD is lacking [13]. We recently reported that
women with a pregnancy complicated by preeclampsia
differed in the genotype distribution of the rs4606 in
RGS2, with a slightly higher proportion of women hav-
ing either the CG or GG genotype, compared to women
who never had a preeclamptic pregnancy [8]. This find-
ing, along with an association between the G allele of
rs4606, reduced RGS2 expression and essential hyperten-
sion, as demonstrated by Semplicini et al. [7], led us to
explore the possible association between this polymor-
phism and hypertension in women with a history of
preeclampsia or uncomplicated pregnancy from our pre-
viously studied population. Our present findings support
an association between the G allele of rs4606 and hyper-
tension after pregnancy by showing that parous women
have an increased risk of developing severe hyperten-
sion, in particular stage 2 systolic hypertension [11], if
they have either the CG or GG genotype, compared to
women with the CC genotype. Our data further showed
that the association to current stage 2 systolic hyperten-
sion was strongest among individuals homozygous for the
G allele, suggesting an allele dose–response relationship.
Merging of women with a history of preeclampsia and
women without a history of preeclampsia is not without
limitations, as these groups represent two highly selectedTable 5 Prevalence of women with hypertension according to
stratification
Systolic blood p
≥90 mmHg
Hard physical activity CC
0 - < 1 h/week 24.9 (202)
≥ 1 h/week 17.5 (59)
P‡ 0.006*
*Statistically significant P < 0.05 (Pearson chi-square). †CG/GG genotypes vs. CC gen
§Thereof GG genotype: n = 30. #Thereof GG genotype: n = 11.populations, with preeclamptic women being at higher
risk of later hypertension in general. Obstetric history
was therefore accounted for in the regression model,
and adjustment for a history of preeclampsia did not
affect the significant relationship between genotype and
hypertension. The magnitude of the association between
the CG/GG genotypes and stage 2 hypertension was also
similar in women with a history of preeclampsia and
normotensive pregnancy if analyses were carried out
separately for the two groups. The results did however
not reach statistical significance in either group alone,
which likely is due to limitations in statistical power
resulting from the stratification of analyses. Our results
also suggested a tendency towards a higher risk of milder
hypertension defined as systolic blood pressure ≥140
mmHg and/or diastolic blood pressure ≥90 mmHg and/or
current use of antihypertensive drugs in GG versus CC
genotype carriers, with the strongest association in women
with a history of preeclampsia. It is important to note that
our study population was selected based on a previous
diagnosis of preeclampsia or not, and not based on a
retrospective case–control (hypertensives vs. normoten-
sives) design. This could potentially have diluted an asso-
ciation between genotype and hypertension, especially in
the control group. Our exclusion criteria, such as exclu-
ding women in the MBRN registered with pre-gestational
chronic hypertension, renal disease, heart disease, any
form of diabetes mellitus or non-proteinuric gestational
hypertension, may also have diluted an association bet-
ween genotype and hypertensive phenotype.
In our present study the association between the CG
or GG genotype and stage 2 hypertension was detected
only after multivariate adjustment and an interactionrs4606 genotypes and physical activity/inactivity
ressure ≥140 mmHg and/or diastolic blood pressure
and/or taking antihypertensive drugs (% (n))
CG/GG P†
26.3 (195)§ 0.545
22.4 (74)# 0.112
0.171
otype. ‡Physically active (≥ 1 h/week) vs. physically inactive (0 - < 1 h/week).
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in line with remote hypertension after pregnancy being
the result of multiple factors, with potential interaction
effects. Previous studies have also suggested interactions
between physical activity and genetics on blood pressure
[14]. Moreover, it has been demonstrated that the blood
pressure lowering effect of endurance training is greater
in subjects with initial high blood pressures [14]. Results
from our present study could therefore potentially sug-
gest that in women with hypertension, and in particular
severe, stage 2 hypertension, a more pronounced benefi-
cial effect of physical activity on blood pressure reduc-
tion may be present in reference CC genotype carriers
compared to CG or GG genotype carriers. An alternative
interpretation is that despite being physically active,
women carrying the CG or GG genotype will still be at a
higher “baseline” (genetic) risk of developing hyperten-
sion compared to women carrying the CC genotype. In
contrast, the elevated risk of hypertension associated
with a sedentary lifestyle may dilute the difference in risk
of hypertension that is seen between individuals with
different genotypes, as those being “genetically pro-
tected” (i.e. CC genotype carriers) may significantly in-
crease their risk of hypertension by being physically
inactive, while physical inactivity may not add a similar
risk in those already at risk (i.e. CG/GG genotype
carriers). To our knowledge, no previous studies have in-
vestigated the potential interaction between this poly-
morphism (rs4606) and physical activity with respect to
blood pressure reduction or the risk of hypertension,
neither in women (whether parous or not), nor in men.
Intervention studies are needed in order to elucidate this
association. Nevertheless, all postpartum women should
be encouraged to adhere to an active lifestyle, as physical
activity in general is associated with a reduced risk of
hypertension, in addition to being associated with a re-
duced risk of other lifestyle related conditions, such as
obesity.
Several studies, including previous results from the
HUNT study population, have shown that women with
preeclampsia have more risk factors for CVD than
women with uncomplicated pregnancies both pre-preg-
nancy and post-pregnancy [15,16], the latter also sup-
ported by our present study (Table 1). A history of
preeclampsia remained however a strong predictor of
hypertension after adjustment for the rs4606 genotype,
age and other variables classically found to modulate
CVD risk. This finding suggests that the preeclamptic
event per se, or the presence of other risk factors not ex-
plored in the present study, may additionally increase
the risk of hypertension later in life, and thereby the risk
of CVD.
The RGS2 is a candidate for regulation of signaling
through the Ang II type 1 receptor (AT1-receptor)[17,18]. Hercule et al. demonstrated that deletion of
RGS2 in mice resulted in an augmented response to Ang
II and altered blood pressure regulation, indicating that
signaling by G protein-coupled receptors is abnormally
prolonged [6]. Several studies have shown that increased
Ang II sensitivity and activating autoantibodies against
the AT1-receptor (AT1-AA) are present during and after
preeclampsia [19-23]. Future studies should investigate if
the presence of AT1-AA influences the association of
hypertension and rs4606.
There is epidemiological support for early-onset pre-
eclampsia and recurrent preeclampsia being more strongly
associated with CVD later in life than a diagnosis of pre-
eclampsia in general [4]. Even in our relatively healthy and
young parous population, we found in crude and mini-
mally adjusted analyses respectively, that women with a
history of recurrent-preeclampsia and early-onset pre-
eclampsia were at a significantly increased risk of later de-
veloping hypertension (blood pressure ≥140/90 mmHg,
and/or current use of antihypertensive drugs) if they car-
ried the CG or GG genotype compared to the CC geno-
type. Unfortunately, the very low numbers of women in
the recurrent preeclampsia and early-onset preeclampsia
sub-groups limited further analyses on these groups, such
as exploring other cut-offs for hypertension or performing
comprehensive logistic regression analyses.
We have previously shown an association between the
CG/GG genotype and the presence of uteroplacental
acute atherosis in women with a preeclamptic preg-
nancy, with the strongest association in the early-onset
preeclampsia group [8]. Acute atherosis is characterized
by foam cell accumulation and lipid depositions in de-
cidual segments of spiral arteries, resembling early stages
of atherosclerotic disease [24]. Whether presence of
acute atherosis in pregnancy could reflect an increased
risk of atherosclerotic CVD in the woman later in life is
currently unknown, but we believe a common pathogen-
esis is plausible [24]. Interestingly, Kamide et al. showed
an association between intima media thickening of
carotid artery and polymorphisms in RGS2, including
1891-1892del TC which is in linkage disequilibrium with
the functional variant rs4606 [25]. In the current study,
based on the HUNT2 population, a diagnosis of utero-
placental acute atherosis and risk of future hypertension
or CVD could not be explored, as this is not a routine
clinical examination after delivery. We were also not
able to explore an association between rs4606 and clin-
ical CVD other than for hypertension, as our present
study included very few clinical cardiovascular end-
points, likely due to a relatively young age group at
HUNT2 inclusion, with a mean age of 41 years. Women
with clinical CVD may also self selectively have been un-
derrepresented in the HUNT2 study. Although a genetic
predisposition for hypertension may be more evident for
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of stronger associations in general, or according to preg-
nancy history, between our genotypes studied and hyper-
tension in an older and less healthy (at parity) population.
Some caution is needed when interpreting our fin-
dings. Information on whether or not the study subjects
were taking antihypertensive drugs was based on self-
report. The definition of hypertension in those reporting
no use of antihypertensive drugs was based on readings
at only one time point (at enrollment in the HUNT2
study), using the average of the two last of three blood
pressure readings. In a clinical setting, a diagnosis of
hypertension, and the potential start of pharmacological
treatment, is usually based on repeated measures of ele-
vated blood pressure. Physical activity was also self-
reported, based on a short questionnaire. A validation
study of the physical activity questionnaire in the
HUNT2 study has previously been carried out [26], and
the “hard physical activity” question was found to be a
useful measure of vigorous physical activity. In contrast,
based on results from this report, we did not include the
answer option “light” physical activity in our analyses, as
this question was found to have poor reproducibility and
to have poor correlation with most comparison mea-
sures [26]. Total physical activity level was therefore not
accounted for in the present study. Additionally, for our
study, several women (approx. 700) were lost in the re-
gression analysis due to missing data for the hard phys-
ical activity question. Another limitation of our study
may be the sampling of blood in the non-fasting state in
the HUNT2 study. We decided to include the ratio of
total cholesterol to HDL in our analyses, as it has been
shown that serum concentrations of these lipid com-
pounds are little influenced by recent food intake [27].
Inclusion (as in the multivariate model) or exclusion (as
in the main effects model) of this variable did however
not influence the association shown between the rs4606
and stage 2 hypertension. Despite these limitations, a major
strength of our study is a well-described population-based
cohort (HUNT2), with selection of a healthy parous sub-
group (except for preeclampsia in the case group) and a
large total sample size, enabling the adjustment for several
important postpartum follow-up variables in the HUNT
study, such as age, BMI, smoking, parities and postpartum
diabetes.
Conclusion
In our present study we have shown that the rs4606
CG/GG genotypes of RGS2, in particular the GG geno-
type, are associated with hypertension in women after
pregnancy, even after excluding women who had a preg-
nancy record of chronic hypertension, cardiac or renal
disease or pregestational diabetes mellitus. Our study in
a relatively healthy population therefore strengthens apreviously reported association between the G allele of
this polymorphism and essential hypertension, and for
the first time demonstrates an association between this
polymorphism and hypertension outside of pregnancy in
a Norwegian population. As the CG or GG genotypes
are more prevalent in women with a history of pre-
eclampsia compared to women with a history of nor-
motensive pregnancy, these genotypes may represent
one piece of a puzzle for the epidemiologically reported
higher prevalence of hypertension later life in women
with preeclampsia. Dysregulated angiotensin signaling
could be a potential mechanistic link that merits further
investigation. Thus, this polymorphism in the RGS2
gene may be a common predisposing factor for the de-
velopment of hypertension in pregnancy (preeclampsia)
and hypertension outside of pregnancy. The present
study also support a multifactorial relationship between
preeclampsia and an increased risk of hypertension later
in life, as a history of preeclampsia remained a strong
and independent risk factor for hypertension after ac-
counting for this polymorphism and classical risk factors
for CVD, such as BMI, age and diabetes. The relative
contributions from genetic factors, environmental fac-
tors and pregnancy factors on the long term risk of
hypertension after preeclampsia needs further exami-
nation, and may also differ between populations as well
as within populations.
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